Ventricular arrhythmias

Reference

• Grauer K, Gums J. Ventricular arrhythmias. I. Prevalence, significance, and Indications for treatment J Am Board Flam Pract 1988: 1 (2): 135–42
   PubMedGoogle Scholar
• Grauer K, Gums J. Ventricular arrhythmias, conclusion: newer agents, additional treatment modalities, and overall approach to the problem. J Am Board Fam Pract 1988: 1(4): 267–73
   PubMedGoogle Scholar
• Vaughan EM, Williams DM. Classification of antldysrhythmic drugs. Pharmacol Ther(B)1975: 1(1): 115–38
   Web of Science ®Google Scholar
• Kreeger KW. Hammill SC. New antiarrhythmic drugs: tocainide. mexiletine, flecainide. encainide, and amiodarone. Mayo Clin Proc 1987: 62(11): 1033–50
   PubMed Web of Science ®Google Scholar
• Michelson EL, Dreifus LS. Newer antiarrhythmic drugs. Med Clin North Am 1988: 72(2): 275–319
   PubMed Web of Science ®Google Scholar
• Hasegawa GR. Tocainide: a new oral antiarrhythmic. Drug Intell Clin Pharm 1985: 19(7–8): 514–7
   PubMedGoogle Scholar
• Roden DM, Woosley RL. Drug therapy: tocainide. N Engl J Med 1986: 315(1): 41–5
   PubMed Web of Science ®Google Scholar
• Morginroth J, Nestlco PF, Horowitz LN. A review of the uses and limitations of tocainide: a class IB antiarrhythmic agent Am Heart J 1985: 110(4): 856–63
   PubMed Web of Science ®Google Scholar
• Braun J, Sörgel F, Engelmaler F. et al. Pharmacokinetics of tocainide in patients with severe renal failure. Eur J Clin Pharmacol 1985: 28(6): 665–70
   PubMed Web of Science ®Google Scholar
• Kutalek SP, Morganroth J, Horowitz LN. Tocainide: a new oral antiarrhythmic agent Ann Intem Med 1985: 103(3): 387–91
   PubMed Web of Science ®Google Scholar
• Winkle RA, Mason JW, Harrison DC. Tocainide for drug-resistant ventricular arrhythmias: efficacy, side effects, and lidocaine responsiveness for predicting tocainide success. Am Heart J1980: 100(6 Pt 2): 1031–6
   PubMed Web of Science ®Google Scholar
• Wooaley RL, McDeritt DG, Nies AS, et al. Suppression of ventricular ectopic depolarizations by tocainide. Circulation 1977: 56(6): 980–4
   PubMed Web of Science ®Google Scholar
• Young MD, Hadidlan Z, Horn, et al. Treatment of ventricular arrhythmias with oral tocainide. Am Heart J 1980: 100(6 Pt 2): 1041–5
   PubMed Web of Science ®Google Scholar
• Haffajee CL Alpert JS, Dalen JE. Tocainide for refractory ventricular arrhythmias of myocardial Infarction. Am Heart J 1980: 100(6 Pt 2): 1013–6
   PubMed Web of Science ®Google Scholar
• Roden DM, Reele SB, Higgins SB, et al. Tocainide therapy for refractory ventricular arrhythmias. Am Heart J 1980: 100(1): 15–22
   PubMed Web of Science ®Google Scholar
• Wasenmiller JE, Aronow WS. Effect of tocainide and quinidine on premature ventricular contractions. Clin Pharmacol Ther 1980: 28(4): 431–5
   PubMed Web of Science ®Google Scholar
• Barbey JT. Thompson KA, Echt DS. et al. Tocainide plus quinidine far treatment of ventricular arrhythmias. Am J Cardiol 1988: 61(8): 570–3
   PubMed Web of Science ®Google Scholar
• Hohnlocer SH, Lange HW, Raeder EA, et al. Short-and long-term therapy with tocainide for malignant ventricular tachyarrhythmias. Circulation 1986: 73(1): 143–9
   PubMed Web of Science ®Google Scholar
• Horn HR, Hadidlan Z, Johnson JL, et al. Safety evaluation of tocainide in the American Emergency Use Program. Am Heart J1980: 100(6 Pt 2): 1037–40
   PubMed Web of Science ®Google Scholar
• Jewitt DB. Hemodynamic effects of newer antiarrhythmic drugs. Am Heart J1980: 100(6 Pt 2): 984–9
   PubMed Web of Science ®Google Scholar
• Nyquist O, Forssell G, Nordlander R, et al. Hemodynamic and antiarrhythmic effects of tocainide in patients with acute myocardial infarction. Am Heart J 1980: 100(6 Pt 2): 1000–5
   PubMed Web of Science ®Google Scholar
• Pottage A. Clinical profiles of newer class I antiarrhythmic agents: tocainide, mexiletine. encainide, flecainide and lorcainide. Am J Cardiol 1983: 52(6): 24–31C
   Google Scholar
• Gertx MA. Garton JP, Jennings WH. Aplastic anemia due to tocanide. (Letter) N Engl J Med 1986: 314(9): 583–4
   PubMed Web of Science ®Google Scholar
• Volosin K, Greenberg RM. Greenspan AJ. Tocainide associated agranulocytosis. Am Heart J 1985: 109(6): 1392–3
   PubMed Web of Science ®Google Scholar
• Perlow GM. Jain BP, Pauker SG, et al. Tocainideassociated interstitial pneumonitis. Ann Intem Med 1981: 94(4 Pt 1): 489–90
   PubMed Web of Science ®Google Scholar
• Scbrader BJ, Bagman JL. Mexiletine: a new type I antiarrhythmic agent Drag Intell Clin Pharm 1986: 20(4): 255–60
   PubMed Web of Science ®Google Scholar
• Fenster PE, Comess KA. Pharmacology and clinical use of mexiletine. Pharmacotherapy 1986: 6(1): 1–9
   PubMed Web of Science ®Google Scholar
• Woosiey RL, Wang T, Stone W, et al. Pharmacology, electro physiology, and pharmacokinetics of mexiletine. Am Heart J1984: 107(5 Pt 2): 1058–65
   PubMed Web of Science ®Google Scholar
• Bigger JT Jr. The interaction of mexiletine with other cardiovascular drugs. Am Heart J 1984: 107(5 Pt 2): 1079–85
   PubMed Web of Science ®Google Scholar
• Singh JB. Rasul AM, Shah A, et al. Efficacy of mexiletine in chronic ventricular arrhythmias compared with quinidine: a single-blind, randomized trial. Am J Cardiol 1984: 53(1): 847
   Google Scholar
• Trimarco B, Ricciardelli B, DeLuca N, et al. Disopyramide, mexiletine. and procainamide in the long-term oral treatment of ventricular arrhythmias: antiarrhythmic efficacy and hemodynamic effects. Curr Ther Res 1983: 33(3): 472–87
   Web of Science ®Google Scholar
• Johansson BW, Stavenow L, Hansson A. Long-term clinical experience with mexilctine. Am Heart J 1984: 107(5 Pt 2): 1099–102
   PubMed Web of Science ®Google Scholar
• Mehta J, Conti CR. Mexiletine. a new antiarrhythmic agent for treatment of premature ventricular complexes. Am J Cardiol 1982: 49(2): 455–60
   PubMed Web of Science ®Google Scholar
• Duff HJ, Roden D, Primm RK, et al. Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. Clrcuiation 1983: 67(5): 1124–8
   PubMed Web of Science ®Google Scholar
• Akhtar M. Practical considerations in the treatment of ventricular arrhythmias with mexiletine. Am Heart J 1984: 107(5 Pt 2): 1086–90
   PubMed Web of Science ®Google Scholar
• Hession M, Blum R, Podrld PJ, et al. Mexiletine and tocainide: does response to one predict response to the other? J Am Coll Cardiol 1986: 7(2): 338–43
   PubMed Web of Science ®Google Scholar
• Estes NA 3d. Garan H, Ruskin JN. Electrophysiologic properties of flecainide acetate. Am J Cardiol 1984: 53(5): 26–9B
   Google Scholar
• Chase SL. Sloakey GE. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents. CUn Pharm 1987: 6(11): 839–50[erratum, Clin Pharm 1988: 7(4): 269]
   Google Scholar
• Morganroth J, Horowitz Lit. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 1984: 53(5): 89–94B
   Google Scholar
• Smith GH. Flecainide: a new class lc antidysrhythmic. Drug Intell Clin Pharm 1985: 19(10): 703–7
   PubMedGoogle Scholar
• Doff HJ, Roden DM, Maffucci RJ, et al. Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol 1961: 48(6): 1133–40
   Google Scholar
• Hodges M, Haugland JM, Granrud G, et al. Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent Clrculation 1982: 65(5): 679–85
   PubMedGoogle Scholar
• Anderson JL, Stewart JR. Perry BA, et al. Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med 1981: 305(9): 473–7
   PubMed Web of Science ®Google Scholar
• Lal R. Chapman PD, Naccarelli GV, et al. Flecainide in the treatment of nonsustained ventricular tachycardia. Ann Intern Med 1986: 105(4): 493–8
   PubMed Web of Science ®Google Scholar
• Hodges M, Salerno DM, Granrud G. Flecainide versus quinidine: results of a multlcenter trial Am J Cardiol 1984: 53(5): 66–71B
   Google Scholar
• Flecainide versus quinidine for treatment of chronic ventricular arrhythmias: a multicenter clinical trial. Circulation 1963: 67(5): 1117–23
   Google Scholar
• Kjekshus J, Bathen J, Orning OM, et al. A double-blind, crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes. Am J Cardiol 1984: 53(5): 72–8B
   Google Scholar
• Flecainide Ventricular Tachycardia Study Group. Treatment of resistant ventricular tachycardia with flecainide acetate. Am J Cardiol 1986: 57(15): 1299–304
   PubMed Web of Science ®Google Scholar
• Platia EV, Estes M, Heine DL, et al. Flecalnide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. Am J Cardiol 1985: 55(8): 956–62
   PubMed Web of Science ®Google Scholar
• Anderson JL, Lutz JR. Allison SB. Electrophysiologic and antiarrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia. J Am Coll Cardiol 1983: 2(1): 105–14
   PubMed Web of Science ®Google Scholar
• Chouty F, Coumel P. Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. Am J Cardiol 1988: 62(6): 35–7D
   Google Scholar
• Goy JJ, Kaufmann U, Kappenberger L, et al. Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. Am J Cardiol 1988: 62(6): 38–40D
   Google Scholar
• Nathan AW, Hellestrand KJ, Bexton RS, et al. Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. Am Heart J1984: 107(2): 222–8
   PubMed Web of Science ®Google Scholar
• Josephson MA, Ikeda N, Singh Bit. Effects of flecainide on ventricular function: Clinical and experimental correlations. Am J Cardiol 1964: 53(5): 95–100B
   Google Scholar
• Gentzkow GD, Sullivan JY. Extracsrdiar adverse effects of flecainide. Am J Cardiol 1984: 53(5): 101–5B 58. Anderson JL, Stewart JR. Crevey BJ. A proposal for the cllnical use of flecainide. Am J Cardiol 1984: 53(5): 112–9B
   Google Scholar
• Wehmeyer AE, Thomas RL. Encainide: a new antiarrhythmic agent Drug intell Clin Pharm 1986: 20(1): 9–13
   PubMedGoogle Scholar
• Roden DM, Reele SB. Higgins SB. et al. Total suppression of ventricular arrhythmias by encainide: pharmacokinetic and electrocardiographic characteristics. N Engl J Med 1980: 302(16): 877–82
   PubMed Web of Science ®Google Scholar
• Winkle RA, Peters F, Kates RE, et al. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. Circulation 1981: 64(2): 290–6
   PubMed Web of Science ®Google Scholar
• Morganroth J. Encainide for ventricular arrhythmias: placebo-controlled and standard comparison trials Am J Cardiol 1986: 58(5): 74–82C
   Google Scholar
• Morganroth J, Somberg JC, Pool PE, et al. Comparative study of encainide and qudnidine in the treatment of ventricular arrhythmias. J Am Coll Cardiol 1986: 7(1): 9–16 [erratum, J Am Coll Cardiol 1986: 8(4): 992]
   PubMed Web of Science ®Google Scholar
• Chesnie B, Podrid P. Lawn B, et al. Encainide for refractory ventricular tachyarrhythmia. Am J Cardiol 1983: 52(5): 495–500
   PubMed Web of Science ®Google Scholar
• Sami MH, Derbekyan VA. Lisbona R. Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function. Am J Cardiol 1983: 52(5): 507–11
   PubMed Web of Science ®Google Scholar
• Soyka LF. Safety of encainide far the treatment of ventricular arrhythmias. Am J Cardiol 1986: 58(5): 96–103C
   Web of Science ®Google Scholar
• Roden DM. Rote of the electrocardiogram in determining electrophysiologic end points of drug therapy. Am J Cardiol 1988: 62(12): 34–8H
   Google Scholar
• Marcus FI, Fontaine GH, Frank R. et al. Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone. Am Heart J 1961: 101(4): 480–93
   Google Scholar
• Heger JJ, Prystowsky EN, Jackman WM. et al. Clinical efficacy and electrophysiology during long-term therapy far recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 1981: 305(10): 539–45
   PubMed Web of Science ®Google Scholar
• Leak D, Eydt JN. Amiodarone far refractory cardiac arrhythmias: 10-year study. Can Med Assoc J 1986: 134(5): 495–501
   Web of Science ®Google Scholar
• Smith WM, Lubbe WF, Whitlock RM, et al. Long-term tolerance of amiodarone treatment far cardiac arrhythmias. Am J Cardiol 1966: 57(15): 1288–93
   Google Scholar
• Heger JJ, Prystowaky EN, Miles WM, et al. Clinical use and pharmacology of amiodarone. Med Clin North Am 1984: 68(5): 1339–66
   PubMed Web of Science ®Google Scholar
• McGovern B, Garan H, Ruskin JN. Serious adverse effects of amiodarone. Clin Cardiol 1984: 7(3): 131–7
   PubMed Web of Science ®Google Scholar